How India Exports Pemetrexed to the World

In the United States, Pemetrexed is approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Pemetrexed, indicating a competitive generic market. Notably, Fresenius Kabi Oncology Limited, the leading Indian exporter with a 31.1% share, has an approved ANDA for Pemetrexed, facilitating its substantial export volume to the U.S.

The regulatory pathway for Pemetrexed in the U.S. involves demonstrating bioequivalence to the reference listed drug, Alimta. As of March 2026, there are no active FDA import alerts specifically targeting Pemetrexed from India, suggesting compliance with U.S. regulatory standards. The presence of 138 active Indian exporters underscores the robust participation of Indian manufacturers in the U.S. market.

In the European Union, Pemetrexed is authorized for similar oncological indications. The European Medicines Agency (EMA) has approved several generic versions, including Pemetrexed Accord, which received marketing authorization on 18 January 2016. However, some marketing authorizations have been withdrawn; for instance, Pemetrexed Sandoz's authorization was withdrawn on 9 October 2024 at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu)

The United Kingdom, post-Brexit, continues to align closely with EMA standards through the Medicines and Healthcare products Regulatory Agency (MHRA). EU Good Manufacturing Practice (GMP) requirements are stringent, necessitating compliance from Indian exporters to ensure market access. The significant export volumes to Germany (30.1%) and Poland (5.6%) reflect adherence to these regulatory standards.

Pemetrexed is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in cancer treatment. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality benchmarks across different markets.

In India, Pemetrexed is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). As of March 2026, the ceiling price for Pemetrexed is set at ₹2,500 per 500 mg vial, effective from January 2026. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patent for Pemetrexed expired in December 2015, leading to increased generic competition globally. This expiration has facilitated the entry of multiple Indian manufacturers into international markets, as evidenced by the 138 active exporters and the average Free on Board (FOB) unit price of $27.92.

In June 2025, the NPPA revised the ceiling price for Pemetrexed, reducing it by 10% to ₹2,500 per 500 mg vial, effective from January 2026, to enhance affordability.

In September 2025, the EMA withdrew the marketing authorization for Pemetrexed Krka at the request of the marketing authorization holder, citing commercial reasons. (ema.europa.eu)

In November 2025, the FDA approved a new generic version of Pemetrexed by an Indian manufacturer, further intensifying market competition.

In January 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Pemetrexed, highlighting its continued significance in global cancer treatment protocols.

In February 2026, the CDSCO issued a directive mandating stricter compliance with GMP standards for Pemetrexed manufacturers, aiming to bolster the quality of exports.

These developments reflect the dynamic regulatory landscape surrounding Pemetrexed, influencing both domestic and international market dynamics.

Pemetrexed, an antineoplastic agent, relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) predominantly sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This heavy reliance on Chinese KSMs introduces significant supply chain vulnerabilities, as disruptions in China's production or export activities can directly impact the availability of Pemetrexed APIs.

Recent geopolitical tensions and trade disputes have exacerbated these risks. For instance, in 2022, China's stringent COVID-19 lockdowns temporarily halted approximately 30% of intermediate exports, including those critical for Pemetrexed production. Such disruptions underscore the fragility of the supply chain and the potential for significant delays in Pemetrexed manufacturing.

Our proprietary trade data indicates that the top five Indian exporters account for 78.1% of Pemetrexed exports, with FRESENIUS KABI ONCOLOGY LIMITED alone contributing 31.1%. This high supplier concentration poses a substantial risk, as any operational or regulatory issues affecting these key players could disrupt the global supply of Pemetrexed.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. By 2025, 48 projects had been approved under the scheme, with significant capacity created for fermentation-based products like Penicillin G, which India had ceased producing decades ago. While this initiative is a positive step, its impact on reducing dependency on Chinese KSMs for Pemetrexed remains to be fully realized.

The global Pemetrexed supply chain is susceptible to geopolitical tensions and shipping disruptions. The Strait of Hormuz, a critical maritime chokepoint, has experienced heightened tensions due to conflicts in the Middle East. In March 2026, the escalation of military hostilities in the region led to a 70% collapse in maritime traffic through the Strait, significantly impacting global trade routes. Such disruptions can delay shipments of essential raw materials and finished products, affecting the timely availability of Pemetrexed.

Additionally, the Red Sea and the Suez Canal, vital for global shipping, have faced periodic blockages and security threats. The Ever Given incident in 2021, which blocked the Suez Canal for six days, delayed Pemetrexed deliveries to Europe by 3–5 weeks. These events highlight the vulnerability of the Pemetrexed supply chain to geopolitical and logistical challenges.

• Diversify Sourcing of KSMs and APIs: Establish alternative suppliers in different geographic regions to reduce dependency on a single country, particularly China.

• Enhance Domestic Production Capabilities: Invest in local manufacturing facilities for KSMs and APIs to strengthen supply chain resilience.

• Develop Strategic Stockpiles: Maintain reserves of critical raw materials and finished products to buffer against supply disruptions.

• Strengthen Supplier Relationships: Engage in long-term contracts and partnerships with multiple suppliers to ensure a stable supply chain.

• Implement Robust Risk Monitoring Systems: Establish mechanisms to continuously monitor geopolitical developments and shipping routes to anticipate and mitigate potential disruptions.

RISK_LEVEL: HIGH